EP Patent

EP4119564A1 — Production method of thienopyrimidine derivative

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2023-01-18 · 3y expired

What this patent protects

The present invention relates to a crystalline form of 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea that exhibits an X-ray powder diffraction pattern having 2-theta (2θ…

USPTO Abstract

The present invention relates to a crystalline form of 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea that exhibits an X-ray powder diffraction pattern having 2-theta (2θ) peaks at approximately 8.932°, 16.607°, and 17.328° or peaks expressed in d values (Å) at approximately 9.893, 5.334, and 5.114.

Drugs covered by this patent

Patent Metadata

Patent number
EP4119564A1
Jurisdiction
EP
Classification
—
Expires
2023-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.